ClinicalTrials.gg
RecruitingNCT04367857Updated Apr 8, 2026

ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

An observational study in Covid-19, Coronavirus Infection and Coronavirus, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Columbia University · Observational

How we know

From the registry’s dates

  • Started Apr 2020; still recruiting 6 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in COVID-19 by Columbia University — 2 open to participants now, 4 under way, none of them phase 3. COVID-19 · Columbia University.

Planned enrollment
3rd of 13
1,000 · median 154
Started
2020
with 11 others
Observational
13 of 23
2 open now
Registered
5th of 23
by date

Among the 23 studies in COVID-19 by Columbia University, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 12 that started in 2020, is one of 13 observational ones, and was the 5th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 23 studies in COVID-19 by Columbia University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in COVID-19 by Columbia University, or all of them as a file.
02

Study summary

The novel coronavirus (SARS-CoV-2) has spread all around the world and testing has posed a challenge globally. Health care providers are highly exposed and are an important group to test. On top of these concerns, health care workers are also stressed by the needs on responders in the COVID-19 crisis. The investigators will look at different ways to measure how common COVID-19 is among health care workers, how common is the presence of antibodies by serological tests (also known as serostatus). The investigators will describe health worker mental and emotional well-being and their coping strategies in their institutional settings. Lastly, the investigators will describe how knowing serostatus can affect individuals' mental and emotional well-being and how to cope in the midst of the COVID-19 response. This will help to how to better test and help healthcare workers in the COVID-19 pandemic and prepare for possible future outbreaks.

Read the detailed description

The rapid spread of the novel coronavirus SARS-CoV-2 has resulted in pandemic levels and a global challenge in diagnosing infection. Diagnosing infection, defining recovery and immunity has been challenging. Health care providers in particular are very interested in knowing their status as they are highly exposed, and if infectious, can potentially transmit infection nosocomially (in the healthcare workplace setting) and to their household. In addition to understanding their exposure risk, infectious period, and immunity status, health care workers are reporting high levels of psychosocial distress including anxiety and burnout. The investigators aim to assess the baseline and cumulative seroprevalence of SARS-CoV-2 among health care workers using both quantitative and qualitative serological assays; describe psychosocial well-being and coping strategies among health workers in their institutional settings and describe how knowledge of one's serostatus affect psychosocial well-being, and coping strategies. Findings from this study will inform; 1) use of serological assays and testing algorithms, and 2) approaches to manage psychosocial stress for healthcare workers.

03

Conditions studied

  • Covid-19
  • Coronavirus Infection
  • Coronavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Employee of NewYork-Presbyterian Hospital and its affiliates

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • NewYork-Presbyterian (NYP) healthcare personnel employee or affiliate
  • Understands and reads English

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years of age
  • Mentally and/or physically unable to complete study requirements
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Prior Positive polymerase chain reaction (PCR) and Recovered

    Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.

    Other: COVID-19 Serology · Behavioral: Health Care Worker Survey

  • Never tested, history of COVID-19 Symptoms and Recovered

    Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days

    Other: COVID-19 Serology · Behavioral: Health Care Worker Survey

  • Never tested and current COVID-19 Symptoms

    Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)

    Other: COVID-19 Serology · Behavioral: Health Care Worker Survey

  • Never tested and asymptomatic

    Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker

    Other: COVID-19 Serology · Behavioral: Health Care Worker Survey

Interventions

  • OtherCOVID-19 Serology

    Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19

  • BehavioralHealth Care Worker Survey

    The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.

06

What researchers measure

Primary outcomes

  1. Proportion seropositive

    Percentage of health care workers with positive serological markers to describe patterns in exposure, re-infection, clinical symptom, serological responses among health care workers based on their baseline serological status over a one year period.

    Time frame: Up to 12 months after collection visit

07

Study locations

1 of 1 sites recruiting
  • NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
    • Brett Gray · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Feb 2027, 82 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 82 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2020
First posted
Apr 29, 2020
StartActual
Apr 18, 2020
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04367857
Responsible party
Sponsor
First posted
Apr 29, 2020
Start date
Apr 18, 2020
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Brett Gray
Contact
bg2168@cumc.columbia.edu
212-305-1570
Magdalena Sobieszczyk, MD, MPH
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion